Ed YaworskiChief Technology Officer at Genevant Sciences Corp.
Ed Yaworski is the Chief Technology Officer at Genevant Sciences Corp. where he leads the development of nucleic acid therapeutics utilizing Genevant’s proprietary lipid nanoparticle (LNP) technology or next generation ligand conjugate technology. He has 30 years of experience in the pharmaceutical industry including 20 years working with delivery systems for nucleic acids, during which he helped advance more than a dozen products into clinical trials in the areas of oncology, metabolic disorders, and infectious diseases. Ed is an expert in LNP pharmaceutical development, scale-up, and manufacturing. He is a pioneer of LNP formulation methods and compositions and is an inventor of Genevant’s leading LNP delivery technology. Ed holds an MSc in Chemistry from the University of Manitoba.
Workshop Leader’s Welcome and Opening Remarks, 1:30pmView Session
Expanding Therapeutic Applications of mRNA Technology Through Advancements in Lipid Design for Lipid Nanoparticle Delivery Systems, 1:45pmView Session
Closing Remarks and Discussion, 4:45pmView Session